Quarterly ResultMay 15, 2026, 07:02 AM
Purple Biotech IM1240 Shows Potent Anti-Tumor Activity; Q1 Net Loss $0.1M
AI Summary
Purple Biotech Ltd. announced Q1 2026 financial results and provided an update on its business progress, highlighting new data for its IM1240 tri-specific antibody which demonstrated potent anti-tumor activity across treatment-resistant patient-derived tumor samples. The company also established a CAPTN-3 Scientific Advisory Board and expanded its collaboration with Converge Bio to leverage generative AI for antibody development. Financially, the company reported a net loss of $0.1 million for Q1 2026, a decrease from the prior year, but an increased adjusted operating loss of $2.1 million. Purple Biotech ended the quarter with $6.4 million in cash, providing a runway into 2027.
Key Highlights
- IM1240 tri-specific antibody demonstrated potent anti-tumor activity across all treatment-resistant patient-derived tumor samples.
- Established CAPTN-3 Scientific Advisory Board with leading experts in T-cell engager development, NK cell biology, and translational oncology.
- Expanded collaboration with Converge Bio to apply generative AI to accelerate the design and optimization of next-generation tri-specific antibodies.
- Net Loss for Q1 2026 was $0.1 million, a decrease from $0.5 million in Q1 2025.
- Adjusted Operating Loss for Q1 2026 was $2.1 million, an increase from $1.3 million in Q1 2025.
- Research and Development Expenses increased to $1.2 million in Q1 2026 from $0.8 million in Q1 2025.
- General and Administrative Expenses increased to $1.0 million in Q1 2026 from $0.6 million in Q1 2025.
- Total Cash Position was $6.4 million as of March 31, 2026, expected to provide runway into 2027.
Price Impact
More from PPBT